E
Xilio Therapeutics, Inc. XLO
$0.7204 $0.01141.61%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)
E
Sell 11/13/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 11/13/2023 due to a decline in the volatility index, solvency index and total return index. The quick ratio declined from 4.63 to 3.53.
D
Sell 11/3/2023Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 11/3/2023 due to an increase in the total return index and volatility index.
E
Sell 10/19/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 10/19/2023 due to a decline in the total return index and volatility index.
D
Sell 10/4/2023Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 10/4/2023 due to an increase in the volatility index.
E
Sell 9/14/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 9/14/2023 due to a decline in the volatility index.
D
Sell 8/30/2023Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 8/30/2023 due to an increase in the volatility index.
E
Sell 8/15/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 8/15/2023 due to a decline in the volatility index and solvency index. The quick ratio declined from 5.76 to 4.63, and debt to equity increased from 0.11 to 0.12.
D
Sell 7/31/2023Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 7/31/2023 due to an increase in the total return index and volatility index.
E
Sell 7/11/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 7/11/2023 due to a decline in the volatility index and total return index.
D
Sell 6/23/2023Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 6/23/2023 due to an increase in the volatility index.
E
Sell 6/7/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 6/7/2023 due to a decline in the volatility index and total return index.
D
Sell 5/22/2023Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 5/22/2023 due to an increase in the volatility index.
E
Sell 5/17/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 5/17/2023 due to a decline in the volatility index and total return index.
D
Sell 5/1/2023Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 5/1/2023 due to an increase in the volatility index and total return index.
E
Sell 4/13/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 4/13/2023 due to a decline in the volatility index.
D
Sell 3/29/2023Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E+ on 3/29/2023 due to an increase in the volatility index and total return index.
E
Sell 3/14/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index.
D
Sell 3/7/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to D- from D on 3/7/2023 due to a decline in the growth index, solvency index and volatility index. The quick ratio declined from 8.26 to 5.7, EBIT declined 14.65% from -$20.21M to -$23.17M, and earnings per share declined from -$0.7223 to -$0.8207.
D
Sell 2/9/2023Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and total return index.
E
Sell 2/8/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index.
D
Sell 1/24/2023Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D from D- on 1/24/2023 due to an increase in the volatility index and total return index.
D
Sell 1/6/2023Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to D- from D on 1/6/2023 due to a decline in the volatility index.
D
Sell 12/19/2022Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D from D- on 12/19/2022 due to an increase in the volatility index.
D
Sell 12/2/2022Downgrade
Xilio Therapeutics, Inc. (XLO) was downgraded to D- from D on 12/2/2022 due to a decline in the volatility index.
D
Sell 11/16/2022Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D from D- on 11/16/2022 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.8988 to -$0.7223, and EBIT increased 17.7% from -$24.55M to -$20.21M.
D
Sell 7/1/2022Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to D- from E on 07/01/2022.
E
Sell 4/1/2022Upgraded
Xilio Therapeutics, Inc. (XLO) was upgraded to E from E- on 4/1/2022 due to a significant increase in the solvency index and growth index. The quick ratio increased from 7.75 to 15.5, earnings per share increased from -$21.2746 to -$0.9822, and operating cash flow increased 17.17% from -$20.72M to -$17.16M.
E
Sell 1/18/2022None
Xilio Therapeutics, Inc. (XLO) was downgraded to E- from U on 01/18/2022.
Weiss Ratings